Moderna Sees Unusually High Options Volume (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNA) was the recipient of unusually large options trading activity on Friday. Investors bought 77,577 call options on the company. This represents an increase of approximately 45% compared to the typical volume of 53,337 call options.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna secured a European Commission contract to supply its RSV vaccine to up to 24 million doses across six countries, a meaningful commercial win that could boost near-term revenue and validate its vaccine business. Moderna secures up to 24 million RSV vaccine dose contract with Europe
• Positive Sentiment: RBC Capital raised its price target on Moderna to $45 from $38, reflecting improved sentiment around the company ahead of second-quarter biotech earnings season. RBC Capital Raises its Price Target on Moderna (MRNA)
• Neutral Sentiment: Moderna said it will report second-quarter 2026 results on July 31, giving investors a near-term catalyst for updates on revenue, vaccine demand, and pipeline progress. Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
• Neutral Sentiment: News that Moderna’s mRNA flu vaccine could be ready this fall highlights pipeline optionality, but commercial uptake remains uncertain. Moderna’s mRNA Flu Vaccine Could Be Ready This Fall. Getting It May Be Another Story.
• Negative Sentiment: Despite company-specific positives, Moderna was caught in a broader biotech selloff that pressured shares as investors rotated out of recently hot names. Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
• Negative Sentiment: One analysis warned Moderna may be trading above fair value after its sharp year-to-date rally, citing rich valuation and ongoing losses as risks for the stock. Moderna (MRNA) Stock May Sit Above Fair Value Following Pipeline Expansion

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the sale, the insider directly owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Noubar Afeyan sold 9,263 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $46.84, for a total value of $433,878.92. Following the completion of the transaction, the director directly owned 3,924 shares of the company’s stock, valued at approximately $183,800.16. The trade was a 70.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 125,088 shares of company stock worth $6,193,713 in the last three months. 10.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Moderna by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock worth $1,226,335,000 after buying an additional 399,487 shares in the last quarter. Capital World Investors bought a new stake in shares of Moderna during the fourth quarter worth $378,299,000. Invesco Ltd. raised its position in shares of Moderna by 15.7% during the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock worth $212,223,000 after acquiring an additional 1,115,131 shares during the last quarter. Theleme Partners LLP lifted its stake in shares of Moderna by 2.5% during the third quarter. Theleme Partners LLP now owns 8,068,810 shares of the company’s stock valued at $208,417,000 after acquiring an additional 200,000 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Moderna by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,621,558 shares of the company’s stock valued at $136,290,000 after acquiring an additional 309,126 shares during the period. Institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on MRNA shares. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a report on Thursday, June 18th. Barclays increased their target price on shares of Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 2nd. Piper Sandler lifted their price target on shares of Moderna from $69.00 to $77.00 and gave the company an “overweight” rating in a report on Friday, June 26th. Royal Bank Of Canada boosted their price target on shares of Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a research report on Tuesday. Finally, The Goldman Sachs Group upped their price objective on shares of Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $38.27.

Moderna Price Performance

Shares of Moderna stock traded down $8.65 during trading on Friday, reaching $67.91. The company’s stock had a trading volume of 4,943,024 shares, compared to its average volume of 9,244,232. The stock has a 50-day moving average price of $55.75 and a two-hundred day moving average price of $49.53. The stock has a market capitalization of $26.94 billion, a P/E ratio of -8.34 and a beta of 0.94. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. Moderna has a one year low of $22.28 and a one year high of $85.60.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The company had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. During the same quarter in the previous year, the business posted ($2.52) EPS. The company’s revenue was up 260.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Moderna will post -6.51 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.